“The evaluation of generalized vaccination programs in the healthy pediatric population under the age of 12 must take into account multiple factors, in terms of benefits and risks, both of an individual nature (risk of disease-risk of adverse reaction) and of the population (contribution to the control of the circulation of the infection, vaccination coverage and protection of more fragile subjects). There is a clear need for more data, especially on the possible long-term consequences of Sars-Cov-1 infection in this population “. Covid-19 technical-scientific group of the Inmi Spallanzani of Rome, in a statement published on Facebook after a technical meeting to take stock of the epidemiological situation and the Covid-19 control initiatives.
“On the pediatric population we have seen a ‘population protection’ effect for this age group attributable to the impact of vaccination in the adult population – recalls the Group of experts – In other words, vaccination of the adult population, particularly in school workers, may have contributed to reducing the risk of infection in school age. Furthermore, in the population in this age group, the risk of infection seems to be linked more to family infections than to those in the school environment. The ‘population protection’ effect on children should also be maintained by supporting immunity levels in adults with the third dose of the vaccine. However, it should be noted that the incidence in pediatric cases remains extremely low, while no data on ‘long Covid’ are available in this population “.
The Spallanzani Covid-19 Scientific Technical Group is coordinated by the General Management and sees the participation of the Scientific Directorate, the Health Directorate and the department and operational unit directors. At today’s meeting they attended Francesco Vaia, Andrea Antinori, Enrico Girardi, Fabrizio Palmieri, Gianpiero D’Offizi, Fabrizio Taglietti. Luisa Marchioni, Emanuele Nicastri, Delia Goletti, Francesco Vairo, Vincenzo Puro.
#Covid #Spallanzani #data #needed #vaccine #12s